Weed for sleep and pain: what works, what doesn't.

The honest preamble.

Sleep and pain are the two reasons we hear most often when an adult walks in for the first time. "I can't sleep through the night anymore." "My back has been awful since I retired from line work." "My partner snores and I lie there for two hours." "Can cannabis help?"

The honest answer is the kind of mixed answer most cannabis writing tries to avoid. Some adults describe it as helpful, occasionally, at low doses. The peer-reviewed research is more skeptical than the marketing copy suggests, and shows that effects can change with frequency of use. And for chronic pain specifically, the federal Agency for Healthcare Research and Quality, after reviewing the published evidence, called the benefit small, short-term, and not a clinically validated alternative to other pain treatment.

We are a Michigan adult-use cannabis retailer, not a clinic. So what we are going to do here is lay out what the actual research says, what we tell customers across the counter, and where the line is that should send the conversation to your doctor.

We are not telling you it works. We are telling you what the research and the customer-counter reality actually look like.

What polysomnogram studies show about cannabis and sleep.

Polysomnography is the overnight in-lab measurement of sleep architecture, the actual electrical and physiological signatures of sleep stages. Subjective sleep ("I felt like I slept better") and objective sleep ("the EEG shows you slept better") often disagree. That gap matters here.

A 2025 systematic review and meta-analysis of polysomnographic studies of cannabis and sleep, published in Sleep Medicine Reviews, identified eighteen studies, nine suitable for meta-analysis. The finding: cannabis administration does not consistently alter sleep duration, sleep latency, wake time, sleep efficiency, or sleep staging.¹ Early studies suggested cannabis suppresses REM sleep, but those were small-scale trials with very high THC doses and methodological limitations. More recent studies with larger samples and lower therapeutic doses report mixed or no evidence of REM suppression.

A 2024 study in the Journal of Clinical Sleep Medicine measured 177 adults using polysomnography after assessing their cannabis use proximal to sleep. The headline result: cannabis use within three hours of bedtime was associated with increased wake-after-sleep-onset (median 60.5 versus 45.8 minutes among non-users) and increased proportion of stage 1 (lightest) sleep.² Frequent users (more than 20 days per month) had increased REM latency and decreased sleep efficiency on top of that.

Translated: heavy or close-to-bed cannabis use can make objective sleep worse, even when the user reports it feels better. That is one of the most counterintuitive findings in this research, and it is the single most important thing customers asking about cannabis for sleep should know.

The tolerance trap.

The same Babson et al. systematic review of cannabinoids on sleep³ noted a consistent pattern across the literature: tolerance develops to the sleep-aiding effects of cannabis with repeated use, and withdrawal from regular cannabis use is associated with significant sleep disturbance, including reduced total sleep time, prolonged sleep onset latency, and REM rebound (vivid, sometimes disturbing dreams).

Plain-English version: the product that helped on day one can be making sleep worse three months in, and quitting it can make the next two weeks of sleep miserable while your sleep architecture renormalizes. This is a real pattern. It is the reason we tell customers who ask about cannabis for sleep that "occasional, low-dose" is a different proposition than "nightly, for years."

What customers describe when they have decided to try low-dose cannabis for evening wind-down.

Assuming the doctor conversation is done and your physician has cleared it, here are the patterns customers have described to us over years of counter conversation. None of this is medical advice or a recommendation to use cannabis for any condition. It is a description of what regulars have told us they have noticed.

• Customers most often describe reaching for edibles or tinctures over smoking for this use case. The cited pharmacokinetic research is consistent: inhalation gets in and out of the bloodstream in two to three hours, edibles and tinctures last 4 to 6 hours.
• Customers who describe an evening wind-down routine typically describe taking it 60 to 90 minutes before bed, not in bed. The cited edible onset window is 30 to 90 minutes (Babson et al. 2017³).
• Customers who describe positive experiences most often describe starting at the low end of cited dose ranges. The University of Michigan's National Poll on Healthy Aging documents 2.5mg per serving as the consensus comfort range for adults new to cannabis or returning after a long break. Most adult-use Michigan edibles come in 10mg doses.
• Customers describe occasional, not nightly, use as the pattern that holds up. The Babson et al. systematic review³ documents tolerance development to the sleep-aiding effects of cannabis with repeated use.
• Customers describe paying attention to how the morning feels, not just how the night felt. Subjective sleep and objective sleep architecture often disagree per the polysomnogram research above.
• Drug-drug interactions in the sedative category are well-documented in the broader medical literature. Talk to your doctor before combining cannabis with alcohol, antihistamines, sleeping pills, or other sedatives, especially if you are an older adult.

Indica or sativa for sleep?

This question comes up at our counter at least daily. The honest answer is that the indica-versus-sativa distinction is closer to folk taxonomy than peer-reviewed pharmacology. Modern cannabis chemistry groups products by chemovar (chemical profile, dominant cannabinoid, terpene mix) rather than the indica or sativa label.

The older trade convention is that indica-dominant strains are marketed as more sedating and body-focused, sativa-dominant as more alert and head-focused. The reality: the compounds that drive cannabis effects (THC, CBD, minor cannabinoids, terpenes) vary widely within both categories, and the same strain name at two different dispensaries can have very different chemical profiles.

What we do at the counter: rather than reach for an indica or sativa label, we look at the actual cannabinoid percentages and the terpene panel on the lab certificate of analysis. For customers asking about evening or sleep, we tend to suggest products with myrcene, linalool, or beta-caryophyllene as dominant terpenes, and we tend toward lower-THC, higher-CBD ratios. None of that is a treatment claim. It is what the trade convention suggests, paired with what the customer is asking for.

What the chronic-pain research actually says.

The most authoritative recent source on cannabis for chronic pain is the Agency for Healthcare Research and Quality's Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain (Comparative Effectiveness Review No. 250, McDonagh et al., 2021).⁴ AHRQ is a federal agency. Their systematic reviews are the gold standard for "what does the peer-reviewed evidence actually show, after we exclude the studies with serious methodological problems."

AHRQ's finding on cannabis for chronic pain: there is low-strength evidence that cannabis-based treatments can produce small short-term improvements in pain intensity for some forms of chronic pain, particularly neuropathic (nerve) pain. Adverse events including dizziness, sedation, and cognitive impairment were common across the studies they reviewed. The strongest signal was for products with relatively standardized cannabinoid content; whole-plant cannabis showed less consistent benefit.

What AHRQ's framing means in plain English: their review found low-strength evidence of small short-term pain improvements in some patients with some forms of chronic pain, particularly nerve pain. "Low-strength evidence" is research-grade language for "the studies suggest a pattern but the evidence base is thin and the effect size is modest." Adverse events were common. The research does not support cannabis as a clinically validated first-line treatment for non-cancer chronic pain. Major clinical guidance (American College of Physicians 2025 Best Practice Advice, BMJ Rapid Recommendation 2021) does not recommend cannabis as a primary treatment for chronic noncancer pain.

If you are asking us about cannabis because your primary-care doctor or pain specialist suggested it as part of a broader treatment plan, that is one conversation. If you are asking us because Tylenol and ibuprofen are not cutting it and you want to skip the doctor visit, that is a different conversation and we will tell you to make the appointment first.

What customers tell us, in our years across the counter.

Assuming the doctor conversation is done and your physician has cleared it, here are the patterns customers have described to us over years of conversation. None of this is a treatment claim or a clinical recommendation. It is a description of what regulars have told us they reach for and what they have told us they have noticed.

• Topicals are the category customers describe trying first for localized muscle and joint complaints. Topicals do not enter the bloodstream in meaningful amounts and do not produce intoxicating effects. The cardiovascular effects of cannabis the CDC flags (heart rate, blood pressure) are documented for inhaled and ingested cannabis; topical formulations bypass that pathway because they don't reach systemic circulation. Customers report localized sensation changes without psychoactive effect; we are not claiming a therapeutic outcome.
• Low-dose tinctures (2.5 to 5mg) come up most often for occasional, not nightly, use. Customers describe the use case as "I am keyed up, the day was long, I just want to actually settle." For ongoing chronic insomnia, the polysomnogram research above indicates objective sleep benefits are inconsistent at best, so we steer those customers toward a doctor conversation about chronic insomnia treatment options before they buy.
• Low-dose edibles for evening wind-down show a similar pattern in customer reports. The customers who describe positive experiences most often are the ones who treat it as occasional rather than nightly. This is consistent with the tolerance research cited above.
• Higher-CBD-ratio products are the category customers describe wanting when they want symptom modulation without intoxication. CBD-dominant products do not produce the heart-rate and blood-pressure changes THC-dominant products do (per the 2024 AHA Journal study cited in our other piece). What CBD does or does not do beyond that depends on the dose, the product, and the individual, and is not something we are equipped to claim.

What our customers tell us.

These are real things real customers have said. Not claims we are making.

• "My back is less braced after a day in the garden. The topical is what I reach for."
• "I sleep 30 minutes earlier on nights I take a 5mg gummy at 9 pm. I do not take it every night anymore. My doctor is fine with it."
• "I quit the nightly habit after I read about tolerance. Sleep was worse for two weeks. Then it was better than it had been in a year."
• "My evening glass of wine has become a 2.5mg gummy three nights a week. I told my doctor; they were fine with it."
• "The pain is still there. It is less loud."

None of those are claims we make. They are things our regulars say, and we share them because the gap between "marketing copy promises a miracle" and "research says it is complicated" is the gap most cannabis writing fails to bridge honestly.

When the answer is "no, see your doctor first."

Specific situations where we tell customers that cannabis is not the right next step, and the doctor visit is:

• Chronic pain you have not yet had evaluated by a primary-care doctor or specialist.
• Insomnia that has lasted longer than three months, especially with daytime fatigue. Chronic insomnia has effective treatments (CBT-I is first-line for most adults) that work better than cannabis for ongoing sleep problems.
• Sleep apnea you have not been screened for. Cannabis is not a treatment for apnea, and can theoretically worsen it.
• Active cardiovascular conditions or recent heart events. See our other piece for the AHA cardiovascular research.
• Pain that is new, severe, or accompanied by red-flag symptoms (numbness, weakness, fever, weight loss). Get evaluated.
• Anyone under 21. Adult-use cannabis is legal in Michigan only for adults 21 and older.
• Anyone on blood thinners, antidepressants, antiseizure medications, or blood pressure medications. See our upcoming piece on cannabis and your prescriptions.
• Anyone pregnant or nursing. The FDA strongly warns against any cannabis use in pregnancy or breastfeeding.

A note on what this page is, and isn't.

This is consumer education from a licensed Michigan adult-use cannabis retailer. It is not medical advice. The sources we have cited (AHRQ, J Clin Sleep Med, Sleep Medicine Reviews, NIDA, CDC) are public, government, or peer-reviewed. Read them yourself. The research is still maturing, and we will update this page as it does.

If anything in this piece raised a question we did not answer, walk into Standish or Au Gres any day from 9 to 9 and ask. We will not pretend to be your doctor. We will tell you what we know, point you at the people who can answer the rest, and let you decide.